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Abstract
Background: Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for
the treatment of rheumatoid arthritis (RA). This multicenter, phase II, randomized, double-blind, placebo-controlled,
parallel-group, dose-finding study investigated the efficacy and safety of canakinumab in patients with active RA
despite ongoing therapy at stable doses of methotrexate.
Methods: Patients were randomized to receive one of four regimens, in addition to methotrexate, for 12 weeks:
canakinumab 150 mg subcutaneously (SC) every 4 weeks (q4wk), canakinumab 300 mg SC (2 injections of 150 mg
SC) every 2 weeks, a 600 mg intravenous loading dose of canakinumab followed by 300 mg SC every 2 weeks’,o r
placebo SC every 2 weeks.
Results: Among 274 patients with evaluable efficacy data, the percentage of responders according to American
College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count) was significantly higher with
canakinumab 150 mg SC q4wk than with placebo (26.5% vs. 11.4%, respectively; p = 0.028). Compared to placebo,
this dosage of canakinumab was also associated with significantly more favorable responses at week 12 with
respect to secondary endpoints including the Disease Activity Score 28, scores on the Health Assessment
Questionnaire and Functional Assessment of Chronic Illness Therapy-Fatigue, swollen 28-joint count, and patient’s
and physician’s global assessments of disease activity. No safety concerns were raised with canakinumab therapy,
particularly with regard to infections. Few injection-site reactions occurred.
Conclusion: The addition of canakinumab 150 mg SC q4wk improves therapeutic responses among patients who
have active RA despite stable treatment with methotrexate.
Trial Registration: (ClinicalTrials.gov identifier: NCT00784628)
Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease that can lead to progressive joint destruction and dis-
ability [1]. In the past decade, the use of disease-modifying
antirheumatic drugs (DMARDs), including methotrexate,
has been recognized as the most effective therapy for
RA [1]. Low-dose weekly methotrexate substantially
improves remission rates and has become the most widely
prescribed DMARD [1].
The development of biologic DMARDs has ushered in
a new therapeutic era based on improved knowledge of
the pivotal roles of pro-inflammatory cytokines (e.g.,
tumor necrosis factor [TNF]-a and several interleukins
[ILs], such as IL-6 and IL-1beta) in RA [2,3]. In several
animal models, the administration of antibodies against
IL-1 has been shown to protect against systemic and
local inflammation (e.g., arthritis) and to decrease the
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any medium, provided the original work is properly cited.histopathological findings of inflammation and osteoarti-
cular destruction [2]. IL-1beta is involved in inflamed
synovial tissue from RA patients, and increased levels of
IL-1beta have been documented in the synovial fluid of
patients with RA [3,4]. Treatment with recombinant IL-1
receptor antagonist (IL-1Ra) anakinra has been shown to
be effective in RA; however, its efficacy seems to be lower
as compared to TNF-a inhibitors [5], and its administra-
tion is frequently associated with injection-related
adverse events (AEs) [5].
Canakinumab is a fully human anti-IL-1beta monoclonal
a n t i b o d yw i t hap l a s m ah a l f - l i f eo f3 - 4w e e k st h a ts e l e c -
tively neutralizes the bioactivity of IL-1beta. This agent
has recently been approved by the US Food and Drug
Administration (FDA), by the European Medicines
Agency, in Switzerland, and in other countries for the
treatment of another IL-1beta-driven disease, cryopyrin-
associated periodic syndrome, in which it has demon-
s t r a t e ds i g n i f i c a n ta n dl o n g - l a s t i n ge f f i c a c y[ 6 ] .F u r t h e r
studies have been published showing efficacy of canakinu-
mab in systemic juvenile idiopathic arthritis (SJIA)[7] and
in gouty arthritis in treating pain, signs, and symptoms of
inflammation and preventing recurrent flares [8,9].
Canakinumab was previously assessed as an add-on
therapy in a randomized, double-blind, placebo-controlled,
dose-escalation, proof-of-concept study involving 53
patients with active RA despite ongoing treatment with a
stable dose of methotrexate (≥ 15 mg/wk for ≥ 3 months)
[10]. Analyses of responses to intravenous (IV) doses of
0.3, 1.3, and 10 mg/kg revealed that the highest dose of
canakinumab significantly reduced disease activity (six
patients reached American College of Rheumatology
[ACR] 20, three ACR 50 and two ACR 70) by day 43.
Other findings included onset of action within 3 weeks,
normalization in C-reactive protein (CRP) levels, and a
good tolerability profile including very few to no injection-
site reactions.
In light of these observations, a trial was undertaken
to assess the efficacy and safety of three canakinumab
dose regimens as add-on therapy in patients with active




This trial was designed as a phase II, 12-week, rando-
mized, double-blind, placebo-controlled, parallel-group,
dose-finding study of the efficacy and safety of additional
canakinumab in patients receiving methotrexate for RA.
The study was conducted at 56 centers in Europe and
North America from November 2006 to September 2008.
The primary objective of this trial was to assess the effi-
cacy of three dose regimens of canakinumab compared
to placebo as add-on treatment in patients who had
active RA despite stable treatment with methotrexate at
the maximum tolerated dose (≤ 25 mg/week). Secondary
objectives were to evaluate the onset of effect of canaki-
numab; its effect on components of the ACR criteria,
including a marker of inflammation (high-sensitivity CRP
[hsCRP]) vs. placebo after 12 weeks; its immunogenicity
after 12 weeks of repeated exposure; its pharmacokinetics
and pharmacodynamics (to contribute to decision-
making for phase III studies); and its overall safety and
tolerability.
Patients
Patients were considered eligible for participation in the
trial if they were males or females ≥ 18 years of age who
met the revised 1987 ACR classification criteria for RA
and had symptoms for ≥ 3 months before randomization
[11]. Active RA was defined as ≥ 6 of 28 tender and swol-
len joints with hsCRP ≥ 10 mg/L and/or erythrocyte sedi-
mentation rate (ESR) ≥ 28 mm over the first hour, at the
time of randomization. Patients were also required to be
in functional status classes I, II, or III according to the
ACR 1991 revised criteria [12]. Participants were required
to have been treated with methotrexate at the maximum
tolerated dose (≤ 2 5m g / w e e k )a n da tas t a b l ed o s eo f
≥ 7.5 mg/week for ≥ 12 weeks before randomization.
Patients who had failed treatment with any DMARD,
including any such agent used in combination with meth-
otrexate as well as any biologic agent, were eligible for par-
ticipation after an appropriate washout period before
enrollment. Patients taking systemic corticosteroids, non-
steroidal anti-inflammatory drugs (NSAIDs), including
cyclooxygenase-2 inhibitors, or paracetamol/acetamino-
phen had to have been on stable doses for at least 4 weeks
before randomization. The maximum allowable dose of
systemic corticosteroids was ≤ 10 mg/day prednisone or
an equivalent for ≥ 4 weeks.
Subjects were excluded from participation if they had
previously experienced hypersensitivity to the study
drug or to molecules with similar structures, had under-
gone intra-articular therapy for RA within the previous
4 weeks, were pregnant or breastfeeding, or had a posi-
tive purified protein derivative of tuberculin skin test
without a follow-up negative chest X-ray.
Treatment
Following a screening period of 3 days to 4 weeks,
patients were randomized in a double-blind fashion to
receive one of the following four possible treatments in
addition to methotrexate over 12 weeks: canakinumab
150 mg subcutaneously (SC) every 4 weeks (q4wk), cana-
kinumab 300 mg SC (2 injections of 150 mg SC) every 2
weeks (q2wk), a 600 mg IV loading dose of canakinumab
followed by 300 mg SC q2wk, or placebo SC q2wk. The
canakinumab doses were selected based on the results of
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patients with active RA despite maximum tolerated doses
of methotrexate, as well as on pharmacokinetic/pharma-
codynamic modeling [10].
Study endpoints
The primary efficacy endpoint was the response to treat-
ment according to ACR 50 criteria at 12 weeks. Calcula-
tions were based on 28-joint counts [13]. Secondary
efficacy variables included responses according to the
ACR 20 and ACR 70 at week 12; ACR 20, ACR 50, and
ACR 70 responses at any visit; ACR component variables;
Short Form-36 (SF-36
®); Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F
©); Disease
Activity Score 28 (DAS28, as well as DAS-based European
League Against Rheumatism [EULAR] criteria); and
Health Assessment Questionnaire (HAQ
©).
Samples were taken during the study visits (no pre-
defined time of the day was requested for this) from a
forearm vein (via direct venipuncture or from an indwel-
ling cannula) into a sodium or lithium heparin tube at
each time point. Soluble plasma protein markers related to
the targeted pathway were measured with a multiplex
panel (including among others IL-6, vascular endothelial
growth factor, or IL-1Ra).
Safety was assessed on the basis of AEs and serious
adverse events (SAEs); occurrence of infection; hematolo-
gic parameters; blood biochemistry; urinalysis; evaluations
of antinuclear antibody, and anti-double-stranded DNA
antibody; vital signs; and tolerability. Spleen sonography
was included in the protocol in response to a request from
the FDA, which had expressed concern regarding the fact
that spleen weight was higher in treated male marmosets
than in controls during a 13-week SC experimental study,
even though this occurrence was not replicated in a subse-
quent 26-week IV toxicology study [Unpublished data on
file at Novartis Pharma AG, Basel, Switzerland]. Pharma-
cokinetic/pharmacodynamic parameters and immunogeni-
city were also examined and will be reported elsewhere.
Statistical analyses
Descriptive statistics were used to summarize demo-
graphics and safety by treatment regimen and, where
appropriate, by time point. The primary efficacy variable,
ACR 50 responder rate, was tested for superiority in
canakinumab treatment groups vs. placebo group in the
intent-to-treat population. Each of the canakinumab
groups was compared against the placebo group based
on a logistic regression model with treatment, center,
and baseline DAS28-CRP as covariates. Missing values
were imputed using the last-observation-carried-forward
approach. Secondary variables (DAS28, CRP, and all
ACR component variables) were analyzed using an analy-
sis of covariance fixed-effects model with treatment as
main effect and correcting for the covariates center and
baseline value.
Calculation of sample size determined that 63 patients
w o u l dn e e dt ob er a n d o m i z e d to each treatment group
in order to have 90% power to show a significant differ-
ence between canakinumab treatment groups and pla-
cebo at a 5% level of significance in a 2-sided Fisher’s
exact test. The data were analyzed using version 8.2 of
the SAS statistical package.
Ethical conduct
The study and any amendments were reviewed by the
independent ethics committee or institutional review
board for each center. The study was conducted according
to the ethical principles of the Declaration of Helsinki.
Written informed consent for the study procedures was
obtained from each patient before initiating any study-




Of the 486 patients screened, 209 were excluded in
accordance with enrollment criteria and 277 were ran-
domized to one of the four treatment groups (Figure 1).
A total of 274 patients were treated and had post-base-
line efficacy data recorded (three patients were rando-
mized but not treated due to study discontinuation on
the day of randomization).
D e m o g r a p h i ca n db a s e l i n ec h a r a c t e r i s t i c so ft h es t u d y
participants are summarized in Table 1. Patients rando-
mized to canakinumab 300 mg SC q2wk had the highest
mean age (61 years). The treatment groups were compar-
able with respect to duration of RA, number of DMARDs
previously received, and functional status. The groups had
comparable baseline values with regard to disease charac-
teristics evaluated by DAS28, FACIT-F, and HAQ, as well
as rheumatoid factor (RF), SF-36, ESR, hsCRP, and 100-
mm visual analog scale (VAS) for pain and for physician’s
and patient’s global assessments of disease activity.
Efficacy
As shown in Figure 2, the percentage of ACR 50 respon-
ders at week 12 (the primary endpoint) was significantly
higher with canakinumab 150 mg SC q4wk than placebo
(26.5% vs. 11.4%, respectively; p = 0.028). The response
rate was also higher in patients receiving canakinumab 300
mg SC q2wk (23.4%), but the difference vs. placebo was
not significant. No statistically significant differences were
found for the numbers of ACR 50 responders at week 12
in the 600 mg IV plus 300 mg SC q2wk group or the
300 mg SC q2wk group compared to the placebo group.
Percentages of ACR 20 responders in the canakinu-
mab and placebo groups (a secondary endpoint) are
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tages of ACR 70 responders were higher in the canaki-
numab 150 mg SC q4wk group than in the placebo
group except at week 2. Percentages of ACR 70 respon-
ders in the canakinumab 300 mg SC q2wk group were
higher than in the placebo group at all visits. No signifi-
cant differences between any of the canakinumab dosage
groups and the placebo group were observed with
regard to ACR 70 response rates at 12 weeks.
Significant differences favoring canakinumab 150 mg
SC q4wk vs. placebo were apparent with respect to the
swollen 28-joint count and patient’s and physician’s
global assessments of disease activity (p < 0.05 for all
comparisons; Table 2), as well as the HAQ and DAS28
scores (p < 0.05 for both comparisons; Table 3 and Fig-
ure 3, respectively). The percentage of patients with a
good response on the DAS-based EULAR criteria was
likewise higher with canakinumab 150 mg SC q4wk
(25.0%) than with 300 mg SC q2wk (18.8%), 600 mg IV
loading dose plus 300 mg SC q2wk (12.7%), or placebo
(18.6%). Across the weeks of the study, greater average
decreases in ESR levels compared to baseline were
observed in the three canakinumab treatment groups
than in the placebo group.
Figure 1 Study flow.
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Page 4 of 10Table 1 Baseline demographic and disease characteristics
Variable Canakinumab 150 mg SC
q4wk, n = 69
Canakinumab 300 mg SC
q2wk, n = 64
Canakinumab 300 mg SC
q2wk + 600 mg IV loading
dose, n = 71
Placebo, n = 70
Female sex, n (%) 56 (81.2) 57 (89.1) 60 (84.5) 52 (74.3)
Age, mean (SD) years 57.10 (11.899) 61.02 (12.244) 55.62 (11.236) 57.53 (12.121)
Duration of RA,
mean (SD) years
11.10 (9.476) 10.13 (8.413) 9.83 (8.144) 8.77 (8.837)
Prior DMARDs, n (%)*
0 51 (73.9) 52 (81.3) 50 (70.4) 54 (77.1)
1 15 (21.7) 11 (17.2) 15 (21.1) 13 (18.6)
> 1 3 (4.4) 1 (1.6) 6 (8.7) 3 (4.3)
DAS28, mean (SD)
score
5.937 (0.7644) 5.818 (0.837) 5.978 (0.7151) 5.870 (0.8002)
RF (kIU/L), mean (SD) 250.9 (920.49) 259.4 (396.15) 154.6 (229.11) 180.6 (311.45)
HAQ, mean (SD)
score
1.643 (0.6106) 1.572 (0.6107) 1.613 (0.4879) 1.566 (0.5565)
Number of tender
joints, mean (SD)
15.6 ± 6.00 15.2 ± 6.00 16.8 ± 6.20 16 ± 5.87
Number of swollen
joints, mean (SD)
11.8 (4.29) 11.9 (4.39) 12.4 (4.95) 12.1(4.75)
Abbreviations: DAS28, Disease Activity Score 28, DMARD, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; IV, intravenous; q2wk,
every 2 weeks; q4wk, every 4 weeks; SD, standard deviation; RA, rheumatoid arthritis; RF, rheumatoid factor.
Figure 2 ACR20 and ACR50 responders in the treatment groups. Analysis based on 28-joint counts. *p < 0.05 vs. placebo.
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Page 5 of 10Table 2 Response criteria: LS mean between-treatment difference for canakinumab vs placebo at week 12
Variable Canakinumab 150 mg SC
q4wk, n = 69
Canakinumab 300 mg SC
q2wk, n = 64
Canakinumab 300 mg SC q2wk + 600 mg IV
loading dose, n = 71
Number of tender joints
Baseline, mean (SD) 15.6 (6.00) 15.2 (6.00) 16.8 (6.20)
Difference vs. placebo in LS mean
change (95% CI)
-1.7 (-4.1, 0.6) -0.3 (-2.7, 2.2) 0.2 (-2.1, 2.6)
p-value 0.152 0.837 0.839
Number of swollen joints
Baseline, mean (SD) 11.8 (4.29) 11.9 (4.39) 12.4 (4.95)
Difference vs. placebo in LS mean
change (95% CI)
-1.8 (-3.6, -0.1) -1.9 (-3.7, -0.1) -1.2 (-3.0, 0.6)
p-value 0.040* 0.039* 0.178
RA pain intensity, VAS in mm
Baseline, mean (SD) 61.6 (18.00) 59.7 (19.82) 65.0 (16.21)
Difference vs. placebo in LS mean
change (95% CI)
-6.5 (-14.0, 1.1) -4.7 (-12.3, 3.0) 0.2 (-2.1, 2.6)
p-value 0.091 0.233 0.336
Physicians’ global assessment of disease activity, VAS in mm
Baseline, mean (SD) 65.4 (15.14) 60.1 (17.46) 64.7 (12.93)
Difference vs. placebo in LS mean
change (95% CI)
-8.8 (-16.6, -0.9) -6.4 (-14.4, 1.7) -4.0 (-11.8, 3.8)
p-value 0.029* 0.121 0.316
Patients’ global assessment of disease activity, VAS in mm
Baseline, mean (SD) 63.4 (16.97) 63.6 (20.67) 67.8 (15.94)
Difference vs. placebo in LS mean
change (95% CI)
-7.5 (-14.7, -0.3) -7.4(-14.7, 0.0) -4.5 (-11.7, 2.8)
p-value 0.041* 0.049* 0.226
hsCRP, mg/L
Baseline, mean (SD) 16.62 (18.735) 16.60 (17.050) 6.59 (20.785)
Difference vs. placebo in LS mean
change (95% CI)
-7.3 (-12.5, -2.1) -2.7 (-8.1, 2.6) -4.9 (-10.1, 0.3)
p-value 0.007* 0.313 0.065
*Statistical significance (2-sided) vs. placebo. Statistical model is analysis of covariance adjusting for treatment and center with baseline value as a covariate
Abbreviations: CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; IV, intravenous; LS mean, least-squares mean; q2wk, every 2 weeks; q4wk, every
4 weeks; SC, subcutaneous; SD, standard deviation; VAS, visual analog scale
Table 3 Response criteria: LSM difference between canakinumab and placebo for HAQ and FACIT-F scores at week 12
Variable Canakinumab 150 mg SC
q4wk, n = 69
Canakinumab 300 mg SC
q2wk, n = 64
Canakinumab 300 mg SC q2wk + 600 mg IV
loading dose, n = 71
HAQ score
Baseline, mean (SD) 1.643 (0.6106) 1.572 (0.6106) 1.613 (0.4879)
Difference vs. placebo in LS mean
change (95% CI)
-0.2 (-0.3, 0.0) -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.0)
p-value 0.036* 0.253 0.171
FACIT-F score
Baseline, mean (SD) 25.6 (12.51) 25.8 (11.87) 22.5 (9.26)
Difference vs. placebo in LS mean
change (95% CI)
4.4 (1.3, 7.5) 2.5 (-0.7, 5.6) 3.5 (0.4, 6.7)
p-value 0.006* 0.120 0.028*
*Statistical significance (2-sided) vs. placebo. Statistical model is analysis of covariance adjusting for treatment and center with baseline value as a covariate
Abbreviations: CI, confidence interval; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue; HAQ, Health Assessment Questionnaire; IV, intravenous;
LSM, least-squares mean; q2wk, every 2 weeks; q4wk, every 4 weeks; SC, subcutaneous; SD, standard deviation
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mab treatment groups exhibited trends toward greater
improvement in FACIT-F and SF-36 scores (Tables 3
and 4, respectively). The most favorable changes were
apparent among patients receiving the 150 mg SC q4wk
regimen. At week 12, notable improvement in all cana-
kinumab treatment groups compared to the placebo
group was observed for the SF-36 subscales for bodily
pain, physical functioning, vitality, social functioning,
and mental health. Compared to placebo, significantly
greater improvement in FACIT-F scores was observed
with canakinumab 150 mg SC q4wk, and the 600 mg IV
loading dose plus 300 mg SC q2wk.
Biomarkers
T h em e a s u r e m e n to fs o l u b l ep l a s m ap r o t e i nm a r k e r s
related to the targeted pathway did not elucidate any
biomarker predictors of response. However, blood sam-
pling for biomarkers was not undertaken at a consistent
time.
Safety
A total of 246 patients completed the study. Reasons for
discontinuation are shown in Figure 1. The proportion
of patients who experienced at least one AE was 52.6%
in the overall study population and was lower with
canakinumab 150 mg SC q4wk than in the other three
treatment groups (Table 5). AEs were mostly mild to
moderate in intensity and did not appear to be related
to either dose or age. SAEs or clinically significant AEs
were reported in 4.7% of the overall study population,
with a lower incidence in the canakinumab 150 mg SC
q4wk group than in the other three groups. No deaths
occurred. The number of discontinuations due to AEs
was likewise lowest with canakinumab 150 mg SC q4wk.
No clinically meaningful changes were observed in the
hematologic parameters or in biochemistry or urinary
measurements, relative to baseline. Three patients
(4.2%) in the group receiving canakinumab 600 mg IV
plus 300 mg SC had elevations in alanine transaminase
(ALT) or aspartate transaminase (AST) ≥ 3t i m e st h e
upper limit of normal (ULN). Among these three
patients, only one had an ALT elevation ≥ 3t i m e st h e
ULN, and two had elevations in both ALT and AST ≥ 3
times the ULN. In the group receiving canakinumab 300
Figure 3 DAS28: Treatment difference between canakinumab
groups and placebo (using last observation carried forward),
by visit (intention-to-treat population). *p < 0.04 vs. placebo.
Table 4 Response criteria: SF-36 scores at baseline and at study assessment time points
Variable Canakinumab 150 mg SC
q4wk, n = 71
Canakinumab 300 mg SC
q2wk, n = 64
Canakinumab 300 mg SC
q2wk + 600 mg IV loading
dose, n = 69
Placebo, n = 70
Mean SF-36 physical component summary score
Baseline, mean (SD) 27.19 (7.092) 28.57 (7.497) 26.29 (6.080) 27.48 (6.616)
Week 2, mean (SD) 29.70 (7.944) 28.94 (7.503) 27.86 (6.441) 29.58 (8.438)
Week 4, mean (SD) 30.40 (8.400) 30.87 (8.608) 28.91 (8.445) 29.94 (8.413)
Week 8, mean (SD) 31.48 (9.833) 31.32 (8.230) 28.89 (7.322) 29.44 (8.569)
Week 12, mean (SD) 32.92 (9.922) 31.62 (8.752) 30.33 (7.129) 30.17 (9.221)
Mean SF-36 mental component summary score
Baseline, mean (SD) 44.38 (12.891) 43.40 (11.325) 41.61(10.845) 44.64(12.779)
Week 2, mean (SD) 45.94 (12.518) 46.02 (11.083) 42.37 (10.585) 45.09 (12.834)
Week 4, mean (SD) 46.61 (12.469) 46.14 (12.008) 43.85 (11.433) 46.16 (12.835)
Week 8, mean (SD) 47.41 (12.228) 46.22 (12.762) 44.09 (11.849) 45.82 (12.032)
Week 12, mean (SD) 48.44 (12.421) 46.74 (11.595) 43.05 (11.958) 44.99 (12.294)
Abbreviations: IV, intravenous; q2wk, every 2 weeks; q4wk, every 4 weeks; SC, subcutaneous; SF-36, Short Form-36; SD, standard deviation
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patient (1.6%) had an ALT ≥ 5 times the ULN and AST
≥ 3 times the ULN, another patient (1.6%) had an ALT
≥ 5 times ULN. The patient with ALT ≥ 5 times discon-
tinued the study due to the ALT elevation, for this
patient, an elevated ALT of 1.5 times ULN at baseline
was noted. In all patients, except the patient who dis-
continued, liver enzyme elevations were transient and
returned to normal values during the study. No patients
had ALT/AST elevations with accompanying elevation
of total bilirubin. Spleen sonography showed no signifi-
cant differences in spleen size between the canakinumab
and placebo groups. Most patients had no injection-site
reactions. An absence of a tolerability reaction at any
time during the trial was recorded for 92.8% of the 150
mg SC q4wk group, 93.8% of the 300 mg SC q2wk
group, 94.4% of the 300 mg SC q2wk plus 600 mg IV
loading dose group, and 95.7% of the placebo group.
Mild or moderate injection-site reactions were reported
in 7.2% of the 150 mg SC q4wk group, 6.3% of the 300
mg SC q2wk group, 5.6% of the 300 mg SC q2wk plus
600 mg IV loading dose group, and 2.9% of the placebo
group. No severe reactions occurred.
Discussion
The results of this study demonstrated the efficacy of
additional treatment with canakinumab (150 mg SC
q4wk vs. placebo) in patients with active RA despite
stable treatment with methotrexate. The primary end-
point of this study ACR 50 improvement compared
to placebo was reached with the 150 mg sc q4wk dose.
Efficacy was also confirmed by the analyses of secondary
endpoints (i.e.,C R P ,H A Q ,a n dD A S2 8 ) .T h er e s p o n s e
to this dose of canakinumab increased over time, suggest-
ing that further improvement may be seen with longer-
term treatment. The canakinumab regimen of 150 mg SC
q4wk was also well tolerated, and the safety profile was
comparable to that of placebo. Fewer than 8% of the
patients had injection-site reactions, which were mild
and of short duration. No unusual or opportunistic infec-
tions were observed with canakinumab in comparison to
placebo during this short-term period study.
No dose effect was seen in this study and the canaki-
numab group receiving the additional loading dose did
not demonstrate an increase in efficacy. It is possible
that therapy led to differential up-or down-regulation of
receptors or soluble receptors, including type 2 decoy
receptors, involved in regulation of IL-1beta activity,
thereby resulting in paradoxical effects. Another factor
could have been the relatively modest sample size. The
results could be consistent with a subgroup of canakinu-
mab-responsive patients, although randomization should
have ensured equal distribution amongst dosing groups.
It would be of great importance to identify biomarkers
for patients with a good response to canakinumab,
although our biomarker panel failed to identify any,
potentially limited by technical factors. For example,
diurnal variation in biomarker levels, such as IL-6, may
have influenced the outcome.
The biological role of IL-1b in the disease pathogen-
esis of RA is not fully understood. Data from anakinra
studies suggest that there might be a relatively inferior
biological role of IL-1beta as compared to TNF-a in
this disease. In a meta-analysis by the Cochrane group
including 5 randomized trials involving 2876 patients
(781 on placebo, 2065 on anakinra), anakinra 50-100
mg per day improved symptoms of pain, function, and
stiffness over a 6-month period [5]. Significant
improvements were noted for ACR 20 (38% vs 23% on
placebo), which were considered clinically meaningful,
Table 5 Adverse events in the safety population
Parameter Canakinumab 150 mg SC
q4wk, n = 69
Canakinumab 300 mg SC
q4wk, n = 64
Canakinumab 300 mg SC q2wk + 600 mg
IV loading dose, n = 71
Placebo,
n=7 0
Patients with at least 1 AE,
n (%)
32 (46.4) 35 (54.7) 40 (56.3) 37 (52.9)
Patients with serious AEs,
n (%)*
1 (1.4) 4 (6.3) 3 (4.2) 5 (7.1)
Discontinuations due to
AEs, n (%)
1 (1.4) 3 (4.7) 5 (7.0) 2 (2.9)
Most frequent AEs (in ≥
5% of patients)
Bronchitis, n (%)
- 4 (6.3) - -
Nasopharyngitis, n (%) 4 (5.8) 4 (6.3) 4 (5.6) 4 (5.7)
Upper respiratory tract
infection, n (%)
- - 4 (5.6) -
*Serious AEs: canakinumab 150 mg SC q4wk–thoracic vertebral fracture (n = 1); canakinumab 300 mg SC q2wk–cellulitis, abscess limb (n = 1), diverticulitis (n =
1), soft tissue infection (n = 1); canakinumab 600 mg IV plus 300 mg SC q2wk, gastritis (n = 1), urosepsis (n = 1); placebo–abdominal hernia, obstructive (n = 1),
atrial fibrillation (n = 1), gastric ulcer hemorrhage (n = 1), RA flare (n = 2)
Abbreviations: AE, adverse event; IV, intravenous; q2wk, every 2 weeks; q4wk, every 4 weeks; RA, rheumatoid arthritis; SC, subcutaneous
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Page 8 of 10although modest. ACR 50 was achieved by 18% vs 7%,
and ACR 70 by 7% vs 2% of patients. The ACR 50
rates achieved in our study within 12 weeks in the
canakinumab 150 mg q4wk group (26% vs 11% canaki-
numab vs placebo) compare favorably with the out-
comes reported for anakinra.
In contrast, in SJIA IL-1b plays a major role in disease
pathology in the majority of patients [7]. In addition, IL-
1beta plays also a key role in gouty arthritis inflammation,
making targeted anti-IL-1beta therapy an appropriate
option [14,15]. In a phase II dose-ranging study in patients
with acute gouty arthritis who were unable to receive
NSAIDs and/or colchicine, canakinumab provided more
rapid and sustained pain relief and significantly reduced
the risk of new flares compared with triamcinolone aceto-
nide 40 mg [8].
The findings from this study show that canakinumab
is able to significantly increase the proportion of RA
patients with ACR 50 responses at 12 weeks, even
though the magnitude of effect in the overall study
population was relatively small. The study was subject
to certain limitations, such as rather small sample sizes
per treatment group and short duration of treatment.
Some patients still do not respond to current biologics,
reflecting an unmet medical need. The identification of
patients who will respond remains a challenge. The fact
that different patients experienced a highly favorable
response to canakinumab could lead to the detection of
predictive biomarkers of response in these patients in
future studies.
Conclusion
Canakinumab 150 mg sc q4wk demonstrated significant
efficacy in a subset of RA patients refractory to methotrex-
ate, even though the effect size in the overall study popula-
tion was small. There were no safety concerns (and,
notably, no sign of an increased infection rate). No predic-
tor-of-response biomarker could be discerned in respon-
ders. The identification of biomarkers in responding
patients with RA will hopefully be elucidated by future
research and will allow the next step in the direction of
personalized medicine and elucidate the role of the anti-
IL-1b antibody canakinumab.
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